SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-035027
Filing Date
2021-03-11
Accepted
2021-03-11 16:30:31
Documents
12
Period of Report
2021-03-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm219261d1_8k.htm   iXBRL 8-K 25647
  Complete submission text file 0001104659-21-035027.txt   199087

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA iova-20210305.xsd EX-101.SCH 3175
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE iova-20210305_lab.xml EX-101.LAB 34592
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE iova-20210305_pre.xml EX-101.PRE 22703
5 EXTRACTED XBRL INSTANCE DOCUMENT tm219261d1_8k_htm.xml XML 3620
Mailing Address 999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070
Business Address 999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070 6502607120
IOVANCE BIOTHERAPEUTICS, INC. (Filer) CIK: 0001425205 (see all company filings)

IRS No.: 753254381 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36860 | Film No.: 21733713
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences